The European Medicines Agency recommends a new Alzheimer’s drug developed by Eisai and Biogen.

London, November 14 (Jiji Press) – The European Medicines Agency announced Thursday that its medical product assessment committee has recommended partial marketing approval of lecanemab for the treatment of Alzheimer’s disease.

In July, the pharmaceutical oversight committee gave a negative opinion on the drug developed by pharmaceutical companies Eisai Co. from Japan and Biogen Inc. from the USA.

However, after conducting a new review at the request of both pharmaceutical companies, the committee considered that the drug’s effectiveness outweighed the risks for some patients.

If the European Commission decides to allow its sale, it will be the first Alzheimer’s drug available in the European Union.

The recommendation excludes patients who carry two copies of the ApoE4 gene because they pose a higher risk of side effects such as inflammation and brain hemorrhages, the agency said.

(Copyright The Jiji Press, Ltd.)